Format

Send to

Choose Destination
Pharm Res. 2010 May;27(5):920-32. doi: 10.1007/s11095-010-0098-6. Epub 2010 Mar 16.

Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.

Author information

1
Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Amherst, New York, 14260, USA.

Abstract

PURPOSE:

To develop an integrated mechanism-based modeling approach for the interspecies scaling of pharmacokinetic (PK) and pharmacodynamic (PD) properties of type I interferons (IFNs) that exhibit target-mediated drug disposition (TMDD).

METHODS:

PK and PD profiles of human IFN-beta1a, IFN-beta1b, and IFN-alpha2a in humans, monkeys, rats, and mice from nine studies were extracted from the literature by digitization. Concentration-time profiles from different species were fitted simultaneously using various allometric relationships to scale model-specific parameters.

RESULTS:

PK/PD profiles of IFN-beta1a in humans and monkeys were successfully characterized by utilizing the same rate constant parameters and scaling the volume of the central compartment to body weight using an allometric exponent of 1. Concentration and effect profiles of other IFNs were also well described by changing only the affinity of the drug to its receptor. PK profiles in rodents were simulated using an allometric exponent of -0.25 for the first-order elimination rate constant, and no receptor-binding was included given the lack of cross-reactivity.

CONCLUSIONS:

An integrated TMDD PK/PD model was successfully combined with classic allometric scaling techniques and showed good predictive performance. Several parameters obtained from one IFN can be effectively shared to predict the kinetic behavior of other IFN subtypes.

PMID:
20232116
PMCID:
PMC3176922
DOI:
10.1007/s11095-010-0098-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center